NK cells readily penetrate tumors, are free from the cytokine release syndrome (CRS ... induced pluripotent stem cell (iPSC)-derived NK cell platforms, which are the future of NK-cell therapies.

The AFM13-NK cell treatment was well tolerated, with no identified cases of cytokine release syndrome, immune cell associated neurotoxicity syndrome or graft-versus-host disease. There was one case of ...

One such effector cell in the antiviral response is the Natural Killer (NK) cell, which secretes inflammatory cytokines and directly kills infected cells. The focus of our research is aimed at ...

RNA sequencing of this NK cell population revealed increased expression of genes involved in the signaling pathway of interleukin (IL)-12, a cytokine that mediates NK cells’ cytotoxic function.

Celularity (CELU) announced a publication in the April 4 issue of peer-reviewed journal Frontiers in Immunology, the official journal of the ...

GloboCare announced that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell ...

Research and development activities for NK cell therapies are rapidly evolving, backed by significant advancements in immunotherapy-centric cancer treatment approaches. Unlike other immune cells ...

One such effector cell in the antiviral response is the Natural Killer (NK) cell, which secretes inflammatory cytokines and directly kills infected cells. The focus of our research is aimed at ...

which triggers 4-1BB signaling to stimulate NK cell proliferation and IFN-γ secretion. 4-1BBL is often co-administered with other cytokines to enhance the activation of NK cells. 3. Augment DC antigen ...